Texas Instruments Inc
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +1.75%.
Did TXN Beat Earnings? Q2 2025 Results
Texas Instruments posted a stronger-than-expected second quarter, with results that initially drew applause before a cautious management tone sent shares tumbling roughly 12% in after-hours trading. Revenue of $4.45 billion climbed 16.4% year-over-year, clearing the $4.31 billion consensus by 3.22%, while diluted EPS of $1.41 beat the $1.33 estimate by 6.36%, aided in part by a $0.02 discrete tax benefit. The primary engine behind the quarter was a broad recovery in the industrial end market, which helped lift the Analog segment, TI's largest business, to $3.45 billion in revenue, up 18% year-over-year, with operating profit growing 27% to $1.32 billion. Despite the solid print, investor enthusiasm cooled quickly as management's noticeably more guarded commentary overshadowed the numbers. Looking ahead, TI guided Q3 2025 revenue of $4.45 billion to $4.80 billion and EPS of $1.36 to $1.60, a range that largely aligned with consensus but did little to reassure analysts watching for signs of durable demand momentum beyond the industrial rebound.
- Continued broad recovery in industrial end markets
- 16% year-over-year revenue growth
- 9% sequential revenue growth
- Benefits from 300mm wafer production driving cost advantages
- Analog segment operating profit grew 27% year-over-year
“Revenue increased 9% sequentially, led by continued broad recovery in industrial, and 16% from the same quarter a year ago.”
Texas Instruments CEO, on the earnings call
Forward Guidance & Outlook
For Q3 2025, TI guided revenue in the range of $4.45 billion to $4.80 billion and earnings per share between $1.36 and $1.60. This guidance does not include changes related to recently enacted U.S. tax legislation. The company highlighted continued broad recovery in industrial markets as a key revenue driver.
TXN YoY Financials
TXN Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.